A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

March 31, 2004

Study Completion Date

March 31, 2007

Conditions
HIV Infections
Interventions
BIOLOGICAL

ALVAC-HIV (vCP1452)

experimental vaccine

BIOLOGICAL

LIPO-5

experimental vaccine

Trial Locations (11)

10456

NY Blood Ctr./Bronx CRS, The Bronx

37232

Vanderbilt Vaccine CRS, Nashville

98104

FHCRC/UW Vaccine CRS, Seattle

35294-2041

Alabama Vaccine CRS, Birmingham

Unknown

Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore, Baltimore

Project Brave HIV Vaccine CRS, Baltimore

Saint Louis Univ. School of Medicine, HVTU, St Louis

02115

Brigham and Women's Hosp. CRS, Boston

02215

Fenway Community Health Clinical Research Site (FCHCRS), Boston

14642-0001

Univ. of Rochester HVTN CRS, Rochester

02906

Miriam Hospital's HVTU, Providence

All Listed Sponsors
collaborator

ANRS, Emerging Infectious Diseases

OTHER_GOV

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00076063 - A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines | Biotech Hunter | Biotech Hunter